ZNTL

Zentalis Pharmaceuticals Llc

ZNTL, USA

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

https://zentalis.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ZNTL
stock
ZNTL

Zentalis Pharmaceuticals: Late Stage, Lots Of Cash, Crushed By The Market Seeking Alpha

Read more →
ZNTL
stock
ZNTL

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of "Hold" from Brokerages MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$5.3125

Analyst Picks

Strong Buy

3

Buy

1

Hold

6

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.40

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-10.56 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-8.16 %

Low 2%

High 10%

Debt to Equity

-

Very High

0.29

Low 1

High 0.3

Investors

* Institutions hold a combined 65.48% of the total shares of Zentalis Pharmaceuticals Llc

1.

Matrix Capital Management Company, LLC

(19.3524%)

since

2025/06/30

2.

Millennium Management LLC

(4.8198%)

since

2025/06/30

3.

Vanguard Group Inc

(3.9989%)

since

2025/06/30

4.

Opaleye Management Inc

(2.6676%)

since

2025/06/30

5.

BlackRock Inc

(2.4146%)

since

2025/06/30

6.

Almitas Capital LLC

(2.217%)

since

2025/06/30

7.

TANG CAPITAL MANAGEMENT LLC

(2.1487%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(2.1424%)

since

2025/07/31

9.

Renaissance Technologies Corp

(2.1204%)

since

2025/06/30

10.

Tybourne Capital Management (HK) Ltd

(2.0491%)

since

2025/06/30

11.

Decheng Capital LLC

(1.8345%)

since

2025/06/30

12.

Two Sigma Advisers, LLC

(1.7688%)

since

2025/06/30

13.

D. E. Shaw & Co LP

(1.6602%)

since

2025/06/30

14.

GSA Capital Partners LLP

(1.5712%)

since

2025/06/30

15.

Morgan Stanley - Brokerage Accounts

(1.5217%)

since

2025/06/30

16.

Two Sigma Investments LLC

(1.5153%)

since

2025/06/30

17.

PRIMECAP Management Company

(1.4246%)

since

2025/06/30

18.

Balyasny Asset Management LLC

(1.3459%)

since

2025/06/30

19.

Pfizer Inc

(1.3223%)

since

2025/06/30

20.

Goldman Sachs Group Inc

(1.1947%)

since

2025/06/30

21.

Jacobs Levy Equity Management, Inc.

(1.1888%)

since

2025/06/30

22.

PRIMECAP Odyssey Aggressive Growth

(1.0278%)

since

2025/06/30

23.

Vanguard Institutional Extnd Mkt Idx Tr

(0.8538%)

since

2025/07/31

24.

Fidelity Extended Market Index

(0.4179%)

since

2025/07/31

25.

Vanguard US Opportunities Ins USD Acc

(0.3703%)

since

2025/06/30

26.

Schwab US Small-Cap ETF™

(0.3563%)

since

2025/08/30

27.

Vanguard Strategic Small-Cap Equity Inv

(0.2902%)

since

2025/06/30

28.

Acadian Global Small-Cap Equity CIT Cl A

(0.2316%)

since

2025/03/04

29.

Invesco RAFI US 1500 Small-Mid ETF

(0.2112%)

since

2025/08/29

30.

Fidelity Enhanced Small Cap ETF

(0.1979%)

since

2025/08/29

31.

iShares Micro-Cap ETF

(0.1759%)

since

2025/08/31

32.

Vanguard Health Care ETF

(0.1572%)

since

2025/07/31

33.

Extended Equity Market Fund K

(0.1532%)

since

2025/06/30

34.

Fidelity Total Market Index

(0.1392%)

since

2025/07/31

35.

Multi-Manager Small Cap Eq Strat Inst

(0.1264%)

since

2025/07/31

36.

Fidelity Series Total Market Index

(0.1113%)

since

2025/07/31

37.

Bridgeway Ultra-Small Company Market

(0.1072%)

since

2025/06/30

38.

Spartan Extended Market Index Pool F

(0.096%)

since

2025/07/31

39.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.089%)

since

2025/03/31

40.

NT Ext Equity Mkt Idx Fd - L

(0.0874%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.37

EPS Estimate

-0.5278

EPS Difference

0.1578

Surprise Percent

29.8977%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(6.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(0.5)
Momentum
No Momentum(3)
Net Net
Strong Net-Net(7)
Quality
Low Quality Business(3)
Value
Undervalued(7)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.